Oneness Biotech Co., Ltd. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was TWD 19.89 million compared to TWD 1,016.84 million a year ago. Net loss was TWD 335.25 million compared to net income of TWD 338.49 million a year ago. Basic loss per share from continuing operations was TWD 0.74 compared to basic earnings per share from continuing operations of TWD 0.77 a year ago. Diluted loss per share from continuing operations was TWD 0.74 compared to diluted earnings per share from continuing operations of TWD 0.76 a year ago.
For the six months, sales was TWD 42.08 million compared to TWD 1,036.93 million a year ago. Net loss was TWD 599.93 million compared to net income of TWD 727.03 million a year ago. Basic loss per share from continuing operations was TWD 1.34 compared to basic earnings per share from continuing operations of TWD 1.65 a year ago. Diluted loss per share from continuing operations was TWD 1.34 compared to diluted earnings per share from continuing operations of TWD 1.63 a year ago.